F. Ahmad

发表

Effects of a fast disintegrating/ rapid release oral formulation of sumatriptan on functional ability in patients with migraine

P. Barbanti, D. Boswell, J. Carpay, 2004, Current medical research and opinion.

Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents

Z. Jabbar-Lopez, R. Sidbury, W. Abramovits, 2022, Dermatology and Therapy.

Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus.

J. Silverberg, A. Wollenberg, D. Murrell, 2019, The Journal of allergy and clinical immunology.

Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne.

M. Gooderham, Jerry Tan, D. Thiboutot, 2019, Journal of the American Academy of Dermatology.

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.

T. Bieber, L. Misery, A. Wollenberg, 2020, The New England journal of medicine.

Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study.

J. Schoenen, D. Boswell, J. Carpay, 2004, Clinical therapeutics.

Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study

J. Silverberg, A. Wollenberg, D. Murrell, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances

S. Ständer, G. Yosipovitch, F. Legat, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Pain Free Efficacy of Sumatriptan in the Early Treatment of Migraine

W. Pryse-Phillips, W. Becker, S. Christie, 2006, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Long‐term safety and efficacy of trifarotene 50 μg/g cream, a first‐in‐class RAR‐γ selective topical retinoid, in patients with moderate facial and truncal acne

L. Kemény, J. Fowler, T. Dirschka, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne.

M. Gooderham, Jerry Tan, D. Thiboutot, 2019, Journal of the American Academy of Dermatology.

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.

M. D. de Bruin‐Weller, J. Szepietowski, F. Ahmad, 2023, New England Journal of Medicine.

436 Nemolizumab monotherapy was associated with significant improvements in prurigo activity score in adult patients with moderate-to-severe prurigo nodularis: results from a phase 3 trial (OLYMPIA 2)

L. Naldi, J. Silverberg, G. Yosipovitch, 2023, British Journal of Dermatology.